SCHEMBL23978245

SCHEMBL23978245

O=C(O)c1ccc(COc2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.60
CASP6 P55212 1/20 0.54
HCAR3 P49019 2/20 0.50
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
MAPT P10636 3/20 0.49
NR4A2 P43354 4/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
ALOX5 P09917 1/20 0.48
PTGES2 Q9H7Z7 1/20 0.48
BCL2 P10415 1/20 0.48
NR4A1 P22736 1/20 0.48
NR4A3 Q92570 1/20 0.48
LTA4H P09960 1/20 0.48
HPGD P15428 1/20 0.47
MAP4K4 O95819 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23978042 0.89 MAOB (0.60) MAOBCASP6HCAR3LMNATSHR
SCHEMBL23978010 0.88 NR4A2 (0.60) MAOBCASP6LMNATSHRMAPT
SCHEMBL4175596 0.81 CASP6 (0.58) CASP6HCAR3LMNATSHRMAPT
SCHEMBL30014024 0.80 MAOB (0.53) MAOBCASP6HCAR3LMNATSHR
SCHEMBL26963411 0.80 MAOB (0.53) MAOBCASP6HCAR3LMNATSHR
SCHEMBL14212713 0.79 CASP6 (0.55) CASP6HCAR3LMNATSHRALOX5
SCHEMBL6950169 0.79 CASP6 (0.55) CASP6HCAR3LMNATSHR
SCHEMBL13264670 0.79 CASP6 (0.55) CASP6HCAR3LMNATSHRMAPT
SCHEMBL3125878 0.79 MAOB (0.68) MAOBTSHRMAPTNPC1RAB9A
SCHEMBL16129686 0.78 CASP6 (0.54) CASP6HCAR3LMNATSHRALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11622970-B2 BCL-2 inhibitors and their use as pharmaceuticals Prelude Therapeutics Incorporation (US) 2023-04-11 US disclosed
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED 2021-11-11 US disclosed
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED 2021-11-11 US disclosed
WO-2021222174-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2021-11-04 WO disclosed
WO-2021222174-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS BCL2, BCL2L2, BCL2L1 MAOB 2890/4885CASP6 36/4885HCAR3 4362/4885
US-11622970-B2 BCL-2 inhibitors and their use as pharmaceuticals BCL2, BCL2L2, BCL2L1 MAOB 2890/4885CASP6 36/4885HCAR3 4362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.